Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLF NASDAQ:GHRS NASDAQ:IMTX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$18.56+1.9%$15.70$9.83▼$19.19$171.01M0.6513,221 shs17,706 shsGHRSGH Research$12.63-3.7%$14.00$6.00▼$20.50$682.09M0.97189,749 shs160,583 shsIMTXImmatics$6.00+5.3%$5.99$3.30▼$12.94$692.84M1.02802,619 shs867,197 shsRZLTRezolute$7.72+3.3%$6.47$2.21▼$8.34$649.86M0.03850,329 shs1.33 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+3.23%-4.81%+9.63%+33.90%+10.20%GHRSGH Research+9.80%-2.96%+2.50%+9.34%+57.95%IMTXImmatics-2.06%-1.89%-9.95%-7.17%-55.05%RZLTRezolute-2.86%-6.04%+14.92%+80.87%+42.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$18.56+1.9%$15.70$9.83▼$19.19$171.01M0.6513,221 shs17,706 shsGHRSGH Research$12.63-3.7%$14.00$6.00▼$20.50$682.09M0.97189,749 shs160,583 shsIMTXImmatics$6.00+5.3%$5.99$3.30▼$12.94$692.84M1.02802,619 shs867,197 shsRZLTRezolute$7.72+3.3%$6.47$2.21▼$8.34$649.86M0.03850,329 shs1.33 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+3.23%-4.81%+9.63%+33.90%+10.20%GHRSGH Research+9.80%-2.96%+2.50%+9.34%+57.95%IMTXImmatics-2.06%-1.89%-9.95%-7.17%-55.05%RZLTRezolute-2.86%-6.04%+14.92%+80.87%+42.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 2.67Moderate Buy$23.0023.92% UpsideGHRSGH Research 2.88Moderate Buy$32.00153.37% UpsideIMTXImmatics 2.83Moderate Buy$14.67144.44% UpsideRZLTRezolute 3.20Buy$11.6751.12% UpsideCurrent Analyst Ratings BreakdownLatest FTLF, IMTX, RZLT, and GHRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/15/2025FTLFFitLife BrandsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$39.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$64.47M2.70$1.03 per share17.97$3.93 per share4.72GHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AIMTXImmatics$168.65M4.32$0.26 per share23.33$5.12 per share1.17RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$8.98M$0.8422.1016.87N/A12.63%21.70%13.45%N/AGHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest FTLF, IMTX, RZLT, and GHRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.151.710.81GHRSGH ResearchN/A29.4929.49IMTXImmaticsN/A8.808.80RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%GHRSGH Research56.90%IMTXImmatics64.41%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.40%GHRSGH ResearchN/AIMTXImmaticsN/ARZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableGHRSGH Research1052.03 millionN/AOptionableIMTXImmatics260121.55 millionN/AOptionableRZLTRezolute4087.00 million71.00 millionOptionableFTLF, IMTX, RZLT, and GHRS HeadlinesRecent News About These CompaniesRezolute: FDA Pivotal Trial Alignment Change Further Bolsters ErsodetugSeptember 16 at 4:36 PM | seekingalpha.comRezolute (NASDAQ:RZLT) Stock Price Down 3.6% - Time to Sell?September 16 at 4:32 PM | marketbeat.comRezolute (RZLT) Projected to Post Quarterly Earnings on ThursdaySeptember 16 at 2:11 AM | americanbankingnews.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Here's WhySeptember 13 at 5:58 AM | marketbeat.comCubist Systematic Strategies LLC Grows Stock Holdings in Rezolute, Inc. $RZLTSeptember 13 at 3:23 AM | marketbeat.comRezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 12, 2025 | seekingalpha.comRezolute (RZLT) Expected to Announce Quarterly Earnings on ThursdaySeptember 12, 2025 | marketbeat.comWalleye Capital LLC Decreases Stock Position in Rezolute, Inc. $RZLTSeptember 8, 2025 | marketbeat.comRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC WainwrightSeptember 6, 2025 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,566,587 Shares of Rezolute, Inc. $RZLTSeptember 3, 2025 | marketbeat.comRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismSeptember 2, 2025 | globenewswire.comRezolute Aligns with FDA on Phase 3 Trial DesignSeptember 2, 2025 | tipranks.comVelan Capital Investment Management LP Reduces Stock Holdings in Rezolute, Inc. $RZLTAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 125,000 Shares of Rezolute, Inc. $RZLTAugust 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Still a Buy?August 27, 2025 | marketbeat.comRezolute, Inc. to Present at Upcoming Investor Conferences in September 2025August 27, 2025 | quiverquant.comQRezolute to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTLF, IMTX, RZLT, and GHRS Company DescriptionsFitLife Brands NASDAQ:FTLF$18.56 +0.35 (+1.92%) Closing price 04:00 PM EasternExtended Trading$18.58 +0.02 (+0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.GH Research NASDAQ:GHRS$12.63 -0.48 (-3.66%) Closing price 04:00 PM EasternExtended Trading$12.71 +0.08 (+0.67%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immatics NASDAQ:IMTX$6.00 +0.30 (+5.26%) Closing price 04:00 PM EasternExtended Trading$6.00 0.00 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Rezolute NASDAQ:RZLT$7.72 +0.25 (+3.35%) Closing price 04:00 PM EasternExtended Trading$7.74 +0.03 (+0.32%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
